文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

作者信息

Burak Kelly W, Thomas Melanie B, Zhu Andrew X

机构信息

Liver Unit, Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, Canada.

出版信息

HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x.

DOI:10.1111/j.1477-2574.2010.00186.x
PMID:20590906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2951819/
Abstract
摘要

相似文献

[1]
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

HPB (Oxford). 2010-6

[2]
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

HPB (Oxford). 2010-6

[3]
Major achievements in hepatocellular carcinoma.

Lancet. 2009-2-21

[4]
Review article: the management of hepatocellular carcinoma.

Aliment Pharmacol Ther. 2009-11-19

[5]
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?

J Gastroenterol Hepatol. 2011-11

[6]
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.

Scand J Gastroenterol. 2010-4

[7]
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.

Clin Adv Hematol Oncol. 2016-8

[8]
Current management of hepatocellular carcinoma.

Med Clin North Am. 2009-7

[9]
Contemporary management of hepatocellular carcinoma.

Clin Med (Lond). 2008-8

[10]
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.

Nat Rev Clin Oncol. 2009-9

本文引用的文献

[1]
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

HPB (Oxford). 2010-6

[2]
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Cardiovasc Intervent Radiol. 2009-11-12

[3]
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.

Gastroenterology. 2009-9-18

[4]
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 2009-1

[5]
Sorafenib in advanced hepatocellular carcinoma.

N Engl J Med. 2008-7-24

[6]
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Hepatology. 2008-1

[7]
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

J Hepatol. 2007-3

[8]
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

Cardiovasc Intervent Radiol. 2007

[9]
Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.

J Vasc Interv Radiol. 2005-12

[10]
Management of hepatocellular carcinoma.

Hepatology. 2005-11

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索